Kits, compositions and methods for cell enrichment

A kit for one-step enrichment of myeloid-derived suppressor cells (MDSCs) from a sample comprising target cells and MDSCs, the kit comprising:

• a plurality of antibodies or fragments thereof that bind target cells;
• a blocking agent that blocks unintended binding of the antibodies or fragments thereof by Fc receptors expressed on the target cells;
• and
• a plurality of particles, wherein the plurality of particles are linked or linkable to at least one of the antibodies or fragments thereof,
• wherein the kit recovers at least 40% of the MDSCs in the sample at a purity of about 70% or higher of the MDSCs, as assessed by flow cytometry,
• wherein the target cells comprise B cells, T cells, NK cells, dendritic cells, monocytes/macrophages, mast cells, endothelial cells, granulocytes, red blood cells, and hematopoietic progenitors, and
• wherein the plurality of antibodies comprise
• a) an anti-CD8 antibody, an anti-B220 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-CD24 antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, an anti-cKit antibody, and an anti-F480 antibody,
• b) an anti-CD8 antibody, an anti-B220 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-CD24 antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, and an anti-cKit antibody,
• c) an anti-CD8 antibody, an anti-B220 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-CD24 antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, an anti-cKit antibody, and an anti-CD31 antibody,
• d) an anti-CD8 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-CD24 antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, an anti-cKit antibody, and an anti-CD31 antibody, or
• e) an anti-CD8 antibody, an anti-B220 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, an anti-cKit antibody, and an anti-CD31 antibody.

A method for one-step enrichment of myeloid-derived suppressor cells (MDSCs) from a sample comprising target cells and MDSCs, the method comprising:

• blocking unintended binding of a plurality of antibodies or fragments thereof by Fc receptors on the one or more target cells with a blocking agent;
• contacting the sample with the plurality of antibodies or fragments thereof that bind one or more target cells, and a plurality of particles, wherein the plurality of particles are linked or linkable to at least one of the antibodies or fragments thereof;
• incubating the target cells, antibodies or fragments thereof, and particles to form target cell:particle complexes;
• and
• separating the target cell:particle complexes from the sample to enrich the MDSCs,
• wherein the kit recovers at least 40% of the MDSCs in the sample at a purity of about 70% or higher of the MDSCs, as assessed by flow cytometry,
• wherein the target cells comprise B cells, T cells, NK cells, dendritic cells, mast cells, granulocytes, red blood cells, and hematopoietic progenitors, and
• wherein the plurality of antibodies comprise
• a) an anti-CD8 antibody, an anti-B220 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-CD24 antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, an anti-cKit antibody, and an anti-F480 antibody,
• b) an anti-CD8 antibody, an anti-B220 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-CD24 antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, and an anti-cKit antibody,
• c) an anti-CD8 antibody, an anti-B220 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-CD24 antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, an anti-cKit antibody, and an anti-CD31 antibody,
• d) an anti-CD8 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-CD24 antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, an anti-cKit antibody, and an anti-CD31 antibody, or
• e) an anti-CD8 antibody, an anti-B220 antibody, an anti-Ter-119 antibody, an anti-CD49b antibody, an anti-CD19 antibody, an anti-CD11c antibody, an anti-TCRγ/δ antibody, an anti-TCRα/β antibody, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD2 antibody, an anti-cKit antibody, and an anti-CD31 antibody.